Eribulin Recombinant Monoclonal Antibody

Eribulin is a synthetic macrocyclic ketone analog of halichondrin B, a potent microtubule dynamics inhibitor that has become an important focus in oncology research. As an antimitotic agent, eribulin works by binding to the vinca domain of tubulin and suppressing microtubule polymerization, ultimately leading to cell cycle arrest and apoptosis in rapidly dividing cells. This mechanism has made eribulin-based therapeutics valuable tools in cancer treatment studies, particularly in the development of antibody-drug conjugates where eribulin serves as the cytotoxic payload.

This recombinant monoclonal antibody, clone 45C2G9, offers researchers the consistency and reproducibility that sequence-defined antibody production provides. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures lot-to-lot uniformity, giving you confidence that your experimental results will remain comparable across studies and over time. The antibody was generated against an Eribulin-BSA conjugate and has been purified using affinity chromatography to deliver high-quality reagent performance.

Validation data demonstrates excellent binding characteristics in functional ELISA applications. When tested against immobilized Farletuzumab ecteribulin (MORAb-202), an antibody-drug conjugate containing eribulin as its payload, this antibody exhibited strong binding activity with an EC50 ranging from 0.8548 to 1.015 ng/mL, indicating high sensitivity for detecting eribulin-containing molecules. The recommended ELISA dilution range of 1:5000 to 1:50000 reflects this sensitivity and allows flexibility in assay optimization.

This antibody serves as a valuable tool for researchers investigating antibody-drug conjugate development, pharmacokinetic studies of eribulin-based therapeutics, and quality control applications requiring reliable eribulin detection.